Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elesclomol SCHEMBL2819576 | 0.98 | HSP90AA1 (0.97) | HSP90AA1HSP90AB1ALDH1A1MAPTHPGD | |
| SCHEMBL12354384 | 0.94 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1ALDH1A1MAPTHPGD | |
| SCHEMBL15044796 | 0.92 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1ALDH1A1MAPTHPGD | |
| SCHEMBL13943131 | 0.92 | HSP90AA1 (0.84) | HSP90AA1HSP90AB1ALDH1A1MAPTHPGD | |
| SCHEMBL12808820 | 0.91 | HSP90AA1 (0.84) | HSP90AA1HSP90AB1ALDH1A1MAPTHPGD | |
| SCHEMBL14295109 | 0.90 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1ALDH1A1MAPTHPGD | |
| SCHEMBL14301339 | 0.89 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1ALDH1A1MAPTHPGD | |
| SCHEMBL14301338 | 0.87 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1ALDH1A1MAPTHPGD | |
| SCHEMBL13042587 | 0.87 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1ALDH1A1MAPTRAB9A | |
| SCHEMBL13042596 | 0.87 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260091021-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2026-04-02 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | claimed |
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | PLEXXIKON INC. (US) | 2025-12-30 | — | — | US | claimed |
| WO-2025260130-A1 | COMPOUNDS AND USES THEREOF | THE UNIVERSITY OF MELBOURNE (AU) | 2025-12-26 | — | — | WO | claimed |
| EP-4661876-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | University of Miami (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4654970-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | claimed |
| EP-4654972-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | claimed |
| WO-2022240966-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | OPNA IMMUNO-ONCOLOGY SA (CH) | 2022-11-17 | — | — | WO | claimed |
| CN-115298180-A | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 富雷旭医疗有限责任公司 | 2022-11-04 | — | — | CN | claimed |
| WO-2022200433-A1 | IMIDAZO[1,2-B]PYRIDAZINE BASED TRICYCLIC COMPOUNDS AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-09-29 | — | — | WO | claimed |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | OPNA IMMUNO-ONCOLOGY SA (CH) | 2022-09-20 | — | — | US | claimed |
| CN-115054592-A | Application of compound in preparation of medicine for treating proliferative hepatocellular carcinoma | 复旦大学附属中山医院 | 2022-09-16 | — | — | CN | claimed |
| WO-2022180150-A1 | IMIDAZO[1,2-A]PYRAZINES AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-09-01 | — | — | WO | claimed |
| EP-4027996-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | Seald AS (NO) | 2022-07-20 | — | — | EP | claimed |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2022-05-12 | — | — | US | claimed |
| WO-2022061251-A1 | COMPOUNDS AND METHODS FOR KRAS MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2022-03-24 | — | — | WO | claimed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | PDK1, PDK2, PDK4 | HSP90AA1 939/4885HSP90AB1 634/4885ALDH1A1 629/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | HSP90AA1 2073/4885HSP90AB1 1512/4885ALDH1A1 25/4885 |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ADORA1, ADORA2A | HSP90AA1 3327/4885HSP90AB1 3043/4885ALDH1A1 114/4885 |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | EP300, CREBBP, HDAC11 | HSP90AA1 2040/4885HSP90AB1 1944/4885ALDH1A1 2653/4885 |
| US-20260091021-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | PLK1, BID, ABCB1 | HSP90AA1 1705/4885HSP90AB1 553/4885ALDH1A1 1221/4885 |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | HSP90AA1 3589/4885HSP90AB1 3284/4885ALDH1A1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.